Cancer Immunology Reserch

Cancer Immunol Res. 2024 Dec 10. doi: 10.1158/2326-6066.CIR-24-0514. Online ahead of print. ABSTRACT Tumor-reactive CD4+ T cells often accumulate in the tumor microenvironment (TME) in human cancer, but their functions and roles in antitumor responses remain elusive. Here, we investigated the immunopeptidome of HLA class II-positive (HLA-II+) endometrial cancer with an inflamed TME using a … Read more

Cancer Immunol Res. 2024 Dec 6. doi: 10.1158/2326-6066.CIR-24-0189. Online ahead of print. ABSTRACT The term cancer immunoediting describes the dual role by which the immune system can suppress and promote tumour growth and is divided into three phases: elimination, equilibrium and escape. The role of NK cells has mainly been attributed to the elimination phase. … Read more

Cancer Immunol Res. 2024 Dec 3;12(12):1661. doi: 10.1158/2326-6066.CIR-12-12-WWR. NO ABSTRACT PMID:39623982 | DOI:10.1158/2326-6066.CIR-12-12-WWR

Cancer Immunol Res. 2024 Nov 27. doi: 10.1158/2326-6066.CIR-24-0713. Online ahead of print. ABSTRACT Regulatory T (Treg) cells play key roles in cancer immunity by suppressing a range of antitumor immune responses and contributing to resistance to programmed death (PD)-1 blockade therapy. Given their critical roles in self-tolerance, local control of immunosuppression by Treg cells, such … Read more

Cancer Immunol Res. 2024 Nov 27. doi: 10.1158/2326-6066.CIR-24-0484. Online ahead of print. ABSTRACT The limited infiltration of CD8+ T cells in tumors hampers the effectiveness of T cell-based immunotherapy, yet the mechanisms that limit tumor infiltration by CD8+ T cells remain unclear. Through bulk RNA sequencing of human tumors, we identified a strong correlation between … Read more

Cancer Immunol Res. 2024 Nov 26. doi: 10.1158/2326-6066.CIR-23-0514. Online ahead of print. ABSTRACT Despite recent advances in the treatment of melanoma, many patients with metastatic disease still succumb to their disease. To identify tumor-intrinsic modulators of immunity to melanoma, we performed a whole-genome CRISPR screen in melanoma and identified Setdb1 as well as all components … Read more

Cancer Immunol Res. 2024 Nov 25. doi: 10.1158/2326-6066.CIR-24-0245. Online ahead of print. ABSTRACT Pleural mesothelioma (PM) is a fatal disease with limited treatment options. Recently, PM management has improved with the development of immune checkpoint inhibitors (ICIs). In first-line therapy, dual PD-1 and CTLA-4 blockade enhances tumor control and patient survival compared with chemotherapy. Unfortunately, … Read more

Cancer Immunol Res. 2024 Nov 21. doi: 10.1158/2326-6066.CIR-24-0124. Online ahead of print. ABSTRACT Approximately 70% of patients receiving immune checkpoint blockade therapies develop treatment resistance. Thus, there is a need for the identification of additional immunotherapeutic targets. CD49a is a membrane protein expressed on NK cells and T cells. In this study, we found that … Read more

Cancer Immunol Res. 2024 Nov 15. doi: 10.1158/2326-6066.CIR-24-0273. Online ahead of print. ABSTRACT Natural killer (NK) cell tumor infiltration is associated with good prognosis in patients with metastatic castration-resistant prostate cancer (mCRPC). NK cells recognize and kill targets by a process called natural cytotoxicity. We hypothesized that promoting an antigen-specific synapse with co-activation may enhance … Read more

Cancer Immunol Res. 2024 Nov 14:OF1. doi: 10.1158/2326-6066.CIR-24-1029. Online ahead of print. NO ABSTRACT PMID:39540853 | DOI:10.1158/2326-6066.CIR-24-1029